{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:18:15Z","timestamp":1788887895176,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Else Kr\u00f6ner-Fresenius-Stiftung\/ForTra GmbH","award":["2017_T05"],"award-info":[{"award-number":["2017_T05"]}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40263-024-01070-7","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T09:02:48Z","timestamp":1709110968000},"page":"291-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants"],"prefix":"10.1007","volume":"38","author":[{"given":"Andreas W.","family":"Wolff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Peine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"H\u00f6fler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Zurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Hemker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9362-7096","authenticated-orcid":false,"given":"Paul","family":"Lingor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"1070_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fnmol.2011.00039","volume":"4","author":"L T\u00f6nges","year":"2011","unstructured":"T\u00f6nges L, Koch J-C, B\u00e4hr M, Lingor P. ROCKing regeneration: rho kinase inhibition as molecular target for neurorestoration. Front Mol Neurosci. 2011;4:39. https:\/\/doi.org\/10.3389\/fnmol.2011.00039.","journal-title":"Front Mol Neurosci"},{"key":"1070_CR2","doi-asserted-by":"publisher","first-page":"32418","DOI":"10.1074\/jbc.274.45.32418","volume":"274","author":"M Amano","year":"1999","unstructured":"Amano M, Chihara K, Nakamura N, Kaneko T, Matsuura Y, Kaibuchi K. The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J Biol Chem. 1999;274:32418\u201324. https:\/\/doi.org\/10.1074\/jbc.274.45.32418.","journal-title":"J Biol Chem"},{"key":"1070_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.03.008","volume":"189","author":"JC Koch","year":"2018","unstructured":"Koch JC, Tatenhorst L, Roser A-E, Saal K-A, T\u00f6nges L, Lingor P. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther. 2018;189:1\u201321. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.03.008.","journal-title":"Pharmacol Ther"},{"key":"1070_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.surneu.2006.10.037","volume":"68","author":"Y Suzuki","year":"2007","unstructured":"Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2007;68:126\u201331. https:\/\/doi.org\/10.1016\/j.surneu.2006.10.037. (discussion 131-2).","journal-title":"Surg Neurol."},{"key":"1070_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2005.06.003","volume":"238","author":"M Shibuya","year":"2005","unstructured":"Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci. 2005;238:31\u20139. https:\/\/doi.org\/10.1016\/j.jns.2005.06.003.","journal-title":"J Neurol Sci"},{"key":"1070_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2014.09.101","volume":"177","author":"X Jiang","year":"2014","unstructured":"Jiang X, Wang Y-F, Zhao Q-H, Jiang R, Wu Y, Peng F-H, et al. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study. Int J Cardiol. 2014;177:61\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2014.09.101.","journal-title":"Int J Cardiol"},{"key":"1070_CR7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.jacc.2005.07.047","volume":"46","author":"RM Vicari","year":"2005","unstructured":"Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005;46:1803\u201311. https:\/\/doi.org\/10.1016\/j.jacc.2005.07.047.","journal-title":"J Am Coll Cardiol"},{"key":"1070_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12272-019-01153-w","volume":"42","author":"M-H Lee","year":"2019","unstructured":"Lee M-H, Kundu JK, Chae J-I, Shim J-H. Targeting ROCK\/LIMK\/cofilin signaling pathway in cancer. Arch Pharm Res. 2019;42:481\u201391. https:\/\/doi.org\/10.1007\/s12272-019-01153-w.","journal-title":"Arch Pharm Res"},{"key":"1070_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.31083\/j.jin.2020.04.243","volume":"19","author":"M-F Guo","year":"2020","unstructured":"Guo M-F, Zhang H-Y, Zhang P-J, Liu X-Q, Song L-J, Wei W-Y, et al. Fasudil reduces \u03b2-amyloid levels and neuronal apoptosis in APP\/PS1 transgenic mice via inhibition of the Nogo-A\/NgR\/RhoA signaling axis. J Integr Neurosci. 2020;19:651\u201362. https:\/\/doi.org\/10.31083\/j.jin.2020.04.243.","journal-title":"J Integr Neurosci"},{"key":"1070_CR10","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.4103\/1673-5374.335827","volume":"17","author":"Q Wang","year":"2022","unstructured":"Wang Q, Song L-J, Ding Z-B, Chai Z, Yu J-Z, Xiao B-G, Ma C-G. Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases. Neural Regen Res. 2022;17:2623\u201331. https:\/\/doi.org\/10.4103\/1673-5374.335827.","journal-title":"Neural Regen Res"},{"key":"1070_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.755164","volume":"13","author":"Y Yan","year":"2021","unstructured":"Yan Y, Gao Y, Fang Q, Zhang N, Kumar G, Yan H, et al. Inhibition of Rho kinase by fasudil ameliorates cognition impairment in app\/ps1 transgenic mice via modulation of gut microbiota and metabolites. Front Aging Neurosci. 2021;13: 755164. https:\/\/doi.org\/10.3389\/fnagi.2021.755164.","journal-title":"Front Aging Neurosci."},{"key":"1070_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.191","volume":"5","author":"JC Koch","year":"2014","unstructured":"Koch JC, T\u00f6nges L, Barski E, Michel U, B\u00e4hr M, Lingor P. ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS. Cell Death Dis. 2014;5: e1225. https:\/\/doi.org\/10.1038\/cddis.2014.191.","journal-title":"Cell Death Dis"},{"key":"1070_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fphar.2017.00017","volume":"8","author":"R G\u00fcnther","year":"2017","unstructured":"G\u00fcnther R, Balck A, Koch JC, Nientiedt T, Sereda M, B\u00e4hr M, et al. Rho kinase inhibition with fasudil in the sod1g93a mouse model of amyotrophic lateral sclerosis-symptomatic treatment potential after disease onset. Front Pharmacol. 2017;8:17. https:\/\/doi.org\/10.3389\/fphar.2017.00017.","journal-title":"Front Pharmacol"},{"key":"1070_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.nbd.2014.09.013","volume":"73","author":"K-A Saal","year":"2015","unstructured":"Saal K-A, Koch JC, Tatenhorst L, Szeg\u0151 EM, Ribas VT, Michel U, et al. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson\u2019s disease in vitro and in vivo. Neurobiol Dis. 2015;73:150\u201362. https:\/\/doi.org\/10.1016\/j.nbd.2014.09.013.","journal-title":"Neurobiol Dis."},{"key":"1070_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-016-0310-y","volume":"4","author":"L Tatenhorst","year":"2016","unstructured":"Tatenhorst L, Eckermann K, Dambeck V, Fonseca-Ornelas L, Walle H, Da Lopes FT, et al. Fasudil attenuates aggregation of \u03b1-synuclein in models of Parkinson\u2019s disease. Acta Neuropathol Commun. 2016;4:39. https:\/\/doi.org\/10.1186\/s40478-016-0310-y.","journal-title":"Acta Neuropathol Commun"},{"key":"1070_CR16","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/NEN.0000000000000095","volume":"73","author":"L Tatenhorst","year":"2014","unstructured":"Tatenhorst L, T\u00f6nges L, Saal K-A, Koch JC, Szeg\u0151 \u00c9M, B\u00e4hr M, Lingor P. Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease. J Neuropathol Exp Neurol. 2014;73:770\u20139. https:\/\/doi.org\/10.1097\/NEN.0000000000000095.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1070_CR17","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1093\/brain\/aws254","volume":"135","author":"L T\u00f6nges","year":"2012","unstructured":"T\u00f6nges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego \u00c9M, et al. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson\u2019s disease. Brain. 2012;135:3355\u201370. https:\/\/doi.org\/10.1093\/brain\/aws254.","journal-title":"Brain"},{"key":"1070_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/glia.22601","volume":"62","author":"L T\u00f6nges","year":"2014","unstructured":"T\u00f6nges L, G\u00fcnther R, Suhr M, Jansen J, Balck A, Saal K-A, et al. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia. 2014;62:217\u201332. https:\/\/doi.org\/10.1002\/glia.22601.","journal-title":"Glia"},{"key":"1070_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3233\/JPD-191909","volume":"10","author":"Y-J Yang","year":"2020","unstructured":"Yang Y-J, Bu L-L, Shen C, Ge J-J, He S-J, Yu H-L, et al. Fasudil Promotes \u03b1-synuclein clearance in an aav-mediated \u03b1-synuclein rat model of Parkinson\u2019s disease by autophagy activation. J Parkinsons Dis. 2020;10:969\u201379. https:\/\/doi.org\/10.3233\/JPD-191909.","journal-title":"J Parkinsons Dis"},{"key":"1070_CR20","first-page":"2354","volume":"8","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Zhang Q, Xi J, Xiao B, Li Y, Ma C. Neuroprotective effect of fasudil on inflammation through PI3K\/Akt and Wnt\/\u03b2-catenin dependent pathways in a mice model of Parkinson\u2019s disease. Int J Clin Exp Pathol. 2015;8:2354\u201364.","journal-title":"Int J Clin Exp Pathol"},{"key":"1070_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ejn.13132","volume":"43","author":"Q He","year":"2016","unstructured":"He Q, Li Y, Guo S, Wang Y, Lin W, Zhang Q, et al. Inhibition of Rho-kinase by fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson\u2019s model. Eur J Neurosci. 2016;43:41\u201352. https:\/\/doi.org\/10.1111\/ejn.13132.","journal-title":"Eur J Neurosci"},{"key":"1070_CR22","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1111\/bph.15275","volume":"177","author":"A Lopez-Lopez","year":"2020","unstructured":"Lopez-Lopez A, Labandeira CM, Labandeira-Garcia JL, Mu\u00f1oz A. Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease. Br J Pharmacol. 2020;177:5622\u201341. https:\/\/doi.org\/10.1111\/bph.15275.","journal-title":"Br J Pharmacol"},{"key":"1070_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/bph.12277","volume":"170","author":"M Takata","year":"2013","unstructured":"Takata M, Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, et al. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. 2013;170:341\u201351. https:\/\/doi.org\/10.1111\/bph.12277.","journal-title":"Br J Pharmacol"},{"key":"1070_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jns.2015.03.022","volume":"353","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Zhang Q, Xi J, Li Y, Ma C-G, Xiao B-G. Multitarget intervention of fasudil in the neuroprotection of dopaminergic neurons in MPTP-mouse model of Parkinson\u2019s disease. J Neurol Sci. 2015;353:28\u201337. https:\/\/doi.org\/10.1016\/j.jns.2015.03.022.","journal-title":"J Neurol Sci"},{"key":"1070_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/00498254.2017.1292016","volume":"48","author":"Z Mao","year":"2018","unstructured":"Mao Z, Wu Y, Li Q, Wang X, Liu Y, Di X. Aldehyde oxidase-dependent species difference in hepatic metabolism of fasudil to hydroxyfasudil. Xenobiotica. 2018;48:170\u20137. https:\/\/doi.org\/10.1080\/00498254.2017.1292016.","journal-title":"Xenobiotica"},{"key":"1070_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2176\/nmc.48.241","volume":"48","author":"Y Suzuki","year":"2008","unstructured":"Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir. 2008;48:241\u20137. https:\/\/doi.org\/10.2176\/nmc.48.241. (discussion 247-8).","journal-title":"Neurol Med Chir."},{"key":"1070_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jstrokecerebrovasdis.2004.10.006","volume":"14","author":"Y Hanada","year":"2005","unstructured":"Hanada Y, Kudo H, Kohmura E. Chronologic changes of fasudil hydrochloride and hydroxyfasudil in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2005;14:47\u20139. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2004.10.006.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1070_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11307-013-0695-y","volume":"16","author":"J Taniguchi","year":"2014","unstructured":"Taniguchi J, Seki C, Takuwa H, Kawaguchi H, Ikoma Y, Fujinaga M, et al. Evaluation of Rho-kinase activity in mice brain using N-11Cmethyl-hydroxyfasudil with positron emission tomography. Mol Imaging Biol. 2014;16:395\u2013402. https:\/\/doi.org\/10.1007\/s11307-013-0695-y.","journal-title":"Mol Imaging Biol"},{"key":"1070_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0091270006293767","volume":"47","author":"PH Hinderling","year":"2007","unstructured":"Hinderling PH, Karara AH, Tao B, Pawula M, Wilding I, Lu M. Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract. J Clin Pharmacol. 2007;47:19\u201325. https:\/\/doi.org\/10.1177\/0091270006293767.","journal-title":"J Clin Pharmacol"},{"key":"1070_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340: c332. https:\/\/doi.org\/10.1136\/bmj.c332.","journal-title":"BMJ"},{"key":"1070_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF01535722","volume":"33","author":"J Svedlund","year":"1988","unstructured":"Svedlund J, Sj\u00f6din I, Dotevall G. GSRS\u2013a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129\u201334. https:\/\/doi.org\/10.1007\/BF01535722.","journal-title":"Dig Dis Sci"},{"key":"1070_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jpba.2009.12.028","volume":"52","author":"H Chen","year":"2010","unstructured":"Chen H, Lin Y, Han M, Bai S, Wen S. Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. J Pharm Biomed Anal. 2010;52:242\u20138. https:\/\/doi.org\/10.1016\/j.jpba.2009.12.028.","journal-title":"J Pharm Biomed Anal"},{"key":"1070_CR33","doi-asserted-by":"publisher","unstructured":"Wolff AW, et al. Protocol for a randomized, placebo-controlled, doubleblind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson\u2019s disease (ROCK-PD). Front Aging Neurosci. 2024;16. https:\/\/doi.org\/10.3389\/fnagi.2024.1308577.","DOI":"10.3389\/fnagi.2024.1308577"},{"key":"1070_CR34","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1253\/circj.cj-13-0443","volume":"77","author":"Y Fukumoto","year":"2013","unstructured":"Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013;77:2619\u201325. https:\/\/doi.org\/10.1253\/circj.cj-13-0443.","journal-title":"Circ J"},{"key":"1070_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/00005344-200211000-00013","volume":"40","author":"H Shimokawa","year":"2002","unstructured":"Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002;40:751\u201361. https:\/\/doi.org\/10.1097\/00005344-200211000-00013.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1070_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/acr.21622","volume":"64","author":"A Fava","year":"2012","unstructured":"Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, Boin F. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud\u2019s phenomenon. Arthritis Care Res. 2012;64:925\u20139. https:\/\/doi.org\/10.1002\/acr.21622.","journal-title":"Arthritis Care Res"},{"key":"1070_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3389\/fneur.2020.00173","volume":"11","author":"JC Koch","year":"2020","unstructured":"Koch JC, Kuttler J, Maass F, Lengenfeld T, Zielke E, B\u00e4hr M, Lingor P. Compassionate use of the rock inhibitor fasudil in three patients with amyotrophic lateral sclerosis. Front Neurol. 2020;11:173. https:\/\/doi.org\/10.3389\/fneur.2020.00173.","journal-title":"Front Neurol"},{"key":"1070_CR38","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/chd.12764","volume":"14","author":"H Ruan","year":"2019","unstructured":"Ruan H, Zhang Y, Liu R, Yang X. The acute effects of 30 mg vs 60 mg of intravenous fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension. Congenit Heart Dis. 2019;14:645\u201350. https:\/\/doi.org\/10.1111\/chd.12764.","journal-title":"Congenit Heart Dis"},{"key":"1070_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3233\/JPD-161050","volume":"7","author":"K Knudsen","year":"2017","unstructured":"Knudsen K, Fedorova TD, Bekker AC, Iversen P, \u00d8stergaard K, Krogh K, Borghammer P. Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson\u2019s Disease: a colon transit and volume study. J Parkinsons Dis. 2017;7:359\u201367. https:\/\/doi.org\/10.3233\/JPD-161050.","journal-title":"J Parkinsons Dis"},{"key":"1070_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1046\/j.0306-5251.2001.01389.x","volume":"51","author":"S Mouly","year":"2001","unstructured":"Mouly S, Aymard G, Tillement JP, Caulin C, Bergmann JF, Urien S. Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome\u2014a population pharmacokinetic study. Br J Clin Pharmacol. 2001;51:557\u201365. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01389.x.","journal-title":"Br J Clin Pharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01070-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T06:28:10Z","timestamp":1722839290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01070-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1070"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01070-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"9 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This study was funded by Else Kr\u00f6ner-Fresenius-Stiftung\/ForTra GmbH under grant no. 2017_T05 to Paul Lingor. This project has been supported by the Bundesministerium f\u00fcr Bildung und Forschung (BMBF), grant no. 01GM1704A, 01GM1704B, the Schweizer Nationalfonds (SNF), grant no. 32ER30 17367, and the Minist\u00e8re des Affaires sociales, de la Sant\u00e9 et des Droits des femmes (DGOS), grant no. DGOS2016-SERI E-RARE under the frame of E-Rare-3, the ERA-Net for Research on Rare Diseases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Paul Lingor is an inventor on a patent for the use of Fasudil for the treatment of amyotrophic lateral sclerosis (EP 2825175 B1, US 9.980,972 B2). Gabriela Zurek heads the LC-MS\/MS department of the Medical Laboratory Bremen, where the determination of total fasudil and hydroxyfasudil was performed. All other authors declare that there are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The approval of both, the ethics committee (no. PVN7203) and the German Federal Institute for Drugs and Medical Devices (BfArM) were obtained prior to the start of the clinical trial and the study was performed in accordance with good clinical practice and the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants signed an informed consent form as evidence of consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability Statement"}},{"value":"Paul Lingor developed the trial concept. Paul Lingor, Claus Hemker, and J\u00f6rg Peine wrote the trial protocol. J\u00f6rg Peine coordinated the trial execution. Josef H\u00f6fler detailed the statistical aspects of the study in the study protocol. Josef H\u00f6fler and Andreas Wolff\u00a0performed the statistical analysis. Gabriela Zurek was responsible for the pharmacokinetic analyses. Andreas Wolff and Paul Lingor interpreted the study results. Andreas Wolff wrote the manuscript. All authors critically reviewed the manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}